[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"chain-detail":3,"chain-related-ch60_E20":714,"chain-scenarios-ch60_E20":722,"chain-expert-resolve-ch60_E20":724,"chain-related":745},{"id":4,"name":5,"category":6,"groupCategory":7,"intro":8,"scale":9,"maturity":10,"meta":11,"checkState":391,"version":392,"createdBy":9,"createdAt":393,"updatedAt":394,"nodes":395},"ch60_E20","生物医药产业链","战略性新兴产业","EMERGING","创新药、生物制品、CXO、基因与细胞治疗",null,"成长期",{"counts":12,"source":17,"experts":18,"shaanxi":73,"clusters":74,"maturity":10,"chainCode":154,"bottlenecks":155,"subCategory":317,"key_technologies":318,"national_policies":327},{"clusters":13,"segments":14,"companies":15,"bottlenecks":16},6,9,16,7,"全产业智慧图谱数据库（公开版）",[19,25,30,35,40,46,52,58,62,68],{"org":20,"raw":21,"name":22,"note":23,"title":24},"中国科学院上海药物研究所","陈凯先（中国科学院上海药物研究所），中国科学院院士，药物分子设计与创新药研发战略","陈凯先","药物分子设计与创新药研发战略","中国科学院院士",{"org":26,"name":27,"note":28,"title":29},"中山康方生物医药有限公司","夏瑜","创始人、董事长，双特异性抗体研发（依沃西单抗、卡度尼利单抗","创始人、董事长",{"org":31,"name":32,"note":33,"title":34},"荣昌生物制药股份有限公司","房健民","联合创始人、首席执行官，抗体与ADC新药研发（维迪西妥单抗","联合创始人、首席执行官",{"org":36,"raw":37,"name":38,"note":39,"title":29},"无锡药明康德新药开发股份有限公司","李革（无锡药明康德新药开发股份有限公司），创始人、董事长，医药研发外包（CRDMO）","李革","医药研发外包（CRDMO）",{"org":41,"raw":42,"name":43,"note":44,"title":45},"云南沃森生物技术股份有限公司","李云春（云南沃森生物技术股份有限公司），董事长，疫苗研发与产业化（二价HPV疫苗）","李云春","疫苗研发与产业化（二价HPV疫苗）","董事长",{"org":47,"raw":48,"name":49,"note":50,"title":51},"康希诺生物股份公司","朱涛（康希诺生物股份公司），联合创始人、首席科学官，疫苗研发","朱涛","疫苗研发","联合创始人、首席科学官",{"org":53,"raw":54,"name":55,"note":56,"title":57},"空军军医大学","陈志南（空军军医大学），中国工程院院士，抗体药物与细胞工程","陈志南","抗体药物与细胞工程","中国工程院院士",{"org":53,"raw":59,"name":60,"note":61,"title":57},"张生勇（空军军医大学），中国工程院院士，手性药物合成与催化","张生勇","手性药物合成与催化",{"org":63,"raw":64,"name":65,"note":66,"title":67},"西安交通大学／西安天隆科技","彭年才（西安交通大学／西安天隆科技），教授，核酸提取与PCR检测技术","彭年才","核酸提取与PCR检测技术","教授",{"org":69,"raw":70,"name":71,"note":72,"title":67},"西北大学／西安金磁纳米","崔亚丽（西北大学／西安金磁纳米），教授，磁性纳米材料与生物检测","崔亚丽","磁性纳米材料与生物检测","医药和医疗装备",[75,79,82,85,88,91,93,96,99,102,105,108,112,115,117,120,123,127,130,133,136,139,141,143,146,149,152],{"city":76,"name":77,"level":78},"北京市","中关村生命科学园","国家级",{"city":80,"name":81,"level":78},"苏州市","苏州工业园区",{"city":83,"name":84,"level":9},"滨江","杭州高新技术产业开发区",{"city":86,"name":87,"level":9},"坪山","深圳国家生物产业基地",{"city":89,"name":90,"level":9},"马山","无锡",{"city":76,"name":92,"level":78},"北京经济技术开发区",{"city":94,"name":95,"level":78},"天津市","天津经济技术开发区",{"city":97,"name":98,"level":78},"南京市","南京江北新区生物医药谷",{"city":100,"name":101,"level":78},"杭州市","杭州余杭经济技术开发区",{"city":103,"name":104,"level":78},"连云港市","连云港经济技术开发区",{"city":106,"name":107,"level":78},"西安／杨凌","西安—杨凌国家生物产业基地",{"city":109,"name":110,"level":111},"上海市","上海临港奉贤园区生命蓝湾","市级",{"city":113,"name":114,"level":78},"烟台市","烟台经济技术开发区",{"city":76,"name":116,"level":78},"中关村科技园区大兴生物医药产业基地",{"city":118,"name":119,"level":78},"泰州市","泰州医药高新技术产业开发区",{"city":121,"name":122,"level":78},"昆明市","昆明高新技术产业开发区",{"city":124,"name":125,"level":126},"厦门市","厦门生物医药港","省级",{"city":128,"name":129,"level":78},"武汉市","武汉临空港经济技术开发区",{"city":131,"name":132,"level":78},"广州市","广州国际生物岛",{"city":134,"name":135,"level":78},"青岛市","青岛高新技术产业开发区",{"city":137,"name":138,"level":78},"无锡市","无锡高新技术产业开发区",{"city":97,"name":140,"level":78},"南京江宁经济技术开发区",{"city":97,"name":142,"level":78},"南京经济技术开发区",{"city":144,"name":145,"level":78},"深圳市","深圳市高新技术产业园区",{"city":147,"name":148,"level":78},"西安","西安高新技术产业开发区草堂科技产业园",{"city":150,"name":151,"level":9},"嘉定","上海械谷",{"city":80,"name":153,"level":78},"苏州高新技术产业开发区","E20",[156,189,213,235,254,274,296],{"name":157,"risk":158,"type":9,"status":159,"experts":160,"policies":173,"progress":174,"companies":175,"policy_support":188},"ADC\u002F双抗连接子payload","风险：高","已突破",[161,167],{"org":162,"raw":163,"name":164,"note":165,"title":166},"康方生物","夏瑜（中山康方生物医药有限公司（康方生物）），创始人、董事长，双特异性抗体研发（依沃西单抗、卡度尼利单抗）","夏瑜（中山康方生物医药有限公司","创始人、董事长，双特异性抗体研发（依沃西单抗、卡度尼利单抗）","）",{"org":168,"raw":169,"name":170,"note":171,"title":172},"烟台","房健民（荣昌生物制药（烟台）股份有限公司），联合创始人、首席执行官，抗体与ADC新药研发（维迪西妥单抗）","房健民（荣昌生物制药","联合创始人、首席执行官，抗体与ADC新药研发（维迪西妥单抗）","股份有限公司）",[],"荣昌\u002F百济\u002F君实ADC产品上市",[176,178,181,183,186],{"name":177,"note":168},"荣昌生物制药",{"name":179,"note":180},"四川科伦博泰生物医药股份有限公司","SKB264等ADC",{"name":26,"note":182},"依沃西单抗、卡度尼利单抗",{"name":184,"note":185},"无锡药明合联生物技术有限公司","ADC CDMO",{"name":187,"note":185},"东曜药业有限公司","生物药专项",{"name":190,"risk":158,"type":191,"status":192,"experts":193,"policies":194,"progress":195,"companies":196,"policy_support":212},"高端生物反应器\u002F一次性袋","设备","依赖进口",[],[],"东富龙、楚天科技生物反应器",[197,200,203,206,209],{"name":198,"note":199},"东富龙科技集团股份有限公司","生物制药装备与一次性系统",{"name":201,"note":202},"上海乐纯生物技术股份有限公司","一次性反应袋及耗材",{"name":204,"note":205},"森松国际控股有限公司","生物反应器",{"name":207,"note":208},"上海多宁生物科技股份有限公司","培养基与一次性耗材",{"name":210,"note":211},"上海奥浦迈生物科技股份有限公司","培养基与培养工艺","生物制造",{"name":214,"risk":158,"type":215,"status":159,"experts":216,"policies":217,"progress":218,"companies":219,"policy_support":234},"基因治疗\u002FCAR-T病毒载体制备","工艺技术",[],[],"药明巨诺、传奇生物CAR-T上市",[220,223,226,229,232],{"name":221,"note":222},"药明生基","无锡生基医药科技有限公司，病毒载体CDMO",{"name":224,"note":225},"上海和元生物技术","集团",{"name":227,"note":228},"南京金斯瑞生物科技有限公司","含蓬勃生物，质粒与病毒载体",{"name":230,"note":231},"复星凯特生物科技有限公司","CAR-T生产",{"name":233,"note":231},"上海药明巨诺生物科技有限公司","CGT专项",{"name":236,"risk":158,"type":215,"status":192,"experts":237,"policies":238,"progress":239,"companies":240,"policy_support":9},"基因工程\u002F细胞治疗(CGT)与mRNA",[],[],"国际标杆：诺华Kymriah\u002F吉利德CAR-T；国产CAR-T获批上市、mRNA平台追赶，规模化生产成本与适应症拓展落后",[241,243,245,248,251],{"name":230,"note":242},"阿基仑赛注射液",{"name":233,"note":244},"瑞基奥仑赛注射液",{"name":246,"note":247},"南京传奇生物科技有限公司","西达基奥仑赛",{"name":249,"note":250},"苏州艾博生物科技有限公司","mRNA疫苗平台",{"name":252,"note":253},"石药集团有限公司","mRNA疫苗技术平台",{"name":255,"risk":158,"type":215,"status":192,"experts":256,"policies":257,"progress":258,"companies":259,"policy_support":9},"重组蛋白\u002F抗体试剂与无血清培养基",[],[],"国际标杆：Thermo\u002FLonzo\u002FSigma；国产奥浦迈\u002F诺唯赞\u002F百普赛斯快速替代，高端细胞培养基与层析填料仍部分进口",[260,263,266,269,271],{"name":261,"note":262},"北京义翘神州科技股份有限公司","重组蛋白与抗体",{"name":264,"note":265},"上海百普赛斯生物科技股份有限公司","重组蛋白",{"name":267,"note":268},"南京诺唯赞生物科技股份有限公司","生物试剂",{"name":210,"note":270},"无血清培养基",{"name":272,"note":273},"澳斯康生物","含健顺生物，无血清培养基",{"name":275,"risk":158,"type":215,"status":276,"experts":277,"policies":278,"progress":279,"companies":280,"policy_support":9},"高端医学影像（CT\u002FMRI\u002FPET-CT）","部分突破",[],[],"国际标杆：GE\u002F西门子\u002F飞利浦GPS；国产联影\u002F迈瑞实现高端CT\u002FMRI突破，核心探测器\u002F磁体与高端临床验证仍追赶",[281,284,287,290,293],{"name":282,"note":283},"上海联影医疗科技股份有限公司","CT\u002FMR\u002FPET-CT全线",{"name":285,"note":286},"东软医疗系统股份有限公司","CT\u002FMR",{"name":288,"note":289},"深圳迈瑞生物医疗电子股份有限公司","超声、影像",{"name":291,"note":292},"北京万东医疗科技股份有限公司","DR\u002FMR",{"name":294,"note":295},"明峰医疗系统股份有限公司","CT",{"name":297,"risk":158,"type":215,"status":276,"experts":298,"policies":299,"progress":300,"companies":301,"policy_support":9},"基因测序仪与生命科学上游仪器",[],[],"国际标杆：Illumina\u002F赛默飞；国产华大智造实现测序仪量产，高端仪器\u002F试剂生态仍追赶",[302,305,308,311,314],{"name":303,"note":304},"深圳华大智造科技股份有限公司","高通量测序仪",{"name":306,"note":307},"苏州真迈生物科技有限公司","基因测序仪",{"name":309,"note":310},"成都齐碳科技有限公司","纳米孔测序仪",{"name":312,"note":313},"北京普译生物科技有限公司","纳米孔测序",{"name":315,"note":316},"赛纳生物科技","北京","生物医药（创新药、生物制品）",[319,321,322,323,324,325,326],{"risk":158,"tech":157,"type":9,"status":159,"bottleneck":320,"domestic_status":174},true,{"risk":158,"tech":190,"type":191,"status":192,"bottleneck":320,"domestic_status":195},{"risk":158,"tech":214,"type":215,"status":159,"bottleneck":320,"domestic_status":218},{"risk":158,"tech":236,"type":215,"status":192,"bottleneck":320,"domestic_status":239},{"risk":158,"tech":255,"type":215,"status":192,"bottleneck":320,"domestic_status":258},{"risk":158,"tech":275,"type":215,"status":276,"bottleneck":320,"domestic_status":279},{"risk":158,"tech":297,"type":215,"status":276,"bottleneck":320,"domestic_status":300},[328,334,339,345,351,357,363,369,374,380,384],{"raw":329,"date":330,"name":331,"doc_no":9,"issuer":332,"summary":333},"《国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（国务院办公厅，2025-01）：提出全链条支持创新药械研发上市、优化审评审批与监管的举措","2025-01","国务院办公厅关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见","国务院办公厅","提出全链条支持创新药械研发上市、优化审评审批与监管的举措",{"raw":335,"date":336,"name":337,"doc_no":9,"issuer":332,"summary":338},"《国务院办公厅关于健全药品价格形成机制的若干意见》（国务院办公厅，2026-03）：完善药品价格形成机制，明确“创新不集采、集采非创新”导向","2026-03","国务院办公厅关于健全药品价格形成机制的若干意见","完善药品价格形成机制，明确“创新不集采、集采非创新”导向",{"raw":340,"date":341,"name":342,"doc_no":9,"issuer":343,"summary":344},"《医药工业发展“十五五”规划》（工业和信息化部等，2026-09）：部署创新药、高端医疗器械、生物制造等发展方向与产业目标","2026-09","医药工业发展“十五五”规划","工业和信息化部等","部署创新药、高端医疗器械、生物制造等发展方向与产业目标",{"raw":346,"date":347,"name":348,"doc_no":9,"issuer":349,"summary":350},"《国民健康“十五五”规划》（国务院，2026-07）：统筹健康中国建设与医药服务供给，强化创新药械与医疗服务保障","2026-07","国民健康“十五五”规划","国务院","统筹健康中国建设与医药服务供给，强化创新药械与医疗服务保障",{"raw":352,"date":353,"name":354,"doc_no":9,"issuer":355,"summary":356},"《关于将二价HPV疫苗纳入国家免疫规划的通知》（国家疾控局等，2025-11）：自2025年11月起为适龄女孩免费接种二价HPV疫苗","2025-11","关于将二价HPV疫苗纳入国家免疫规划的通知","国家疾控局等","自2025年11月起为适龄女孩免费接种二价HPV疫苗",{"raw":358,"date":359,"name":360,"doc_no":9,"issuer":361,"summary":362},"《商业健康保险创新药品目录（2025年）》（国家医保局等，2025-12）：建立商保创新药目录机制，拓宽创新药多元支付渠道","2025-12","商业健康保险创新药品目录（2025年）","国家医保局等","建立商保创新药目录机制，拓宽创新药多元支付渠道",{"raw":364,"date":365,"name":366,"doc_no":9,"issuer":367,"summary":368},"《药品试验数据保护实施办法》（国家药品监督管理局，2026-05）：建立药品试验数据保护制度，激励创新药研发","2026-05","药品试验数据保护实施办法","国家药品监督管理局","建立药品试验数据保护制度，激励创新药研发",{"raw":370,"date":353,"name":371,"doc_no":9,"issuer":372,"summary":373},"《关于促进和规范“人工智能+医疗卫生”应用发展的实施意见》（国家卫生健康委等，2025-11）：推动人工智能在医疗健康领域规范化应用，覆盖药物研发与诊疗环节","关于促进和规范“人工智能+医疗卫生”应用发展的实施意见","国家卫生健康委等","推动人工智能在医疗健康领域规范化应用，覆盖药物研发与诊疗环节",{"raw":375,"date":376,"name":377,"doc_no":9,"issuer":378,"summary":379},"《陕西省培育千亿级生物产业创新集群行动计划》（陕西省发展和改革委员会，2024-10）：到2027年全省生物产业规模突破1000亿元，构建西安—杨凌国家生物产业基地“一基地多片区”格局","2024-10","陕西省培育千亿级生物产业创新集群行动计划","陕西省发展和改革委员会","到2027年全省生物产业规模突破1000亿元，构建西安—杨凌国家生物产业基地“一基地多片区”格局",{"raw":381,"date":376,"name":382,"doc_no":9,"issuer":378,"summary":383},"《陕西省培育千亿级高端药品和医疗器械产业创新集群行动计划》（陕西省发展和改革委员会，2024-10）：壮大高端药品和医疗器械产业，布局草堂科技产业园、咸阳医药产业园、汉中生物医药产业园等集聚区","陕西省培育千亿级高端药品和医疗器械产业创新集群行动计划","壮大高端药品和医疗器械产业，布局草堂科技产业园、咸阳医药产业园、汉中生物医药产业园等集聚区",{"raw":385,"date":386,"name":387,"doc_no":388,"issuer":389,"summary":390},"《关于建立省重点产业链“链长制”工作机制的通知》（陕办字〔2024〕20号）（陕西省委办公厅、省政府办公厅，2024）：省级重点产业链优化拓展为34条并建立链长制，含医药和医疗装备等重点产业链","2024","关于建立省重点产业链“链长制”工作机制的通知","陕办字〔2024〕20号","陕西省委办公厅、省政府办公厅","省级重点产业链优化拓展为34条并建立链长制，含医药和医疗装备等重点产业链","VERIFIED",1,"2026-10-12T14:21:59.374Z","2026-10-14T07:01:43.835Z",[396,434,471,509,545,578,611,639,666],{"id":397,"chainId":4,"layer":398,"segment":399,"name":399,"keyPoints":400,"companies":401,"sortOrder":419,"isKey":320,"checkState":391,"meta":420,"createdAt":432,"links":433},"cnH_E20_01","上游","生命科学仪器\u002F试剂","测序仪 质谱 生物反应器 培养基",[402,404,405,406,407,410,413,416],{"name":303,"note":403},"高通量基因测序仪",{"name":306,"note":307},{"name":309,"note":310},{"name":312,"note":313},{"name":408,"note":409},"聚光科技","杭州",{"name":411,"note":412},"北京莱伯泰科仪器股份有限公司","实验室分析仪器",{"name":414,"note":415},"西安天隆科技有限公司","核酸提取仪与PCR检测系统，1997年成立",{"name":417,"note":418},"西安金磁纳米生物技术有限公司","磁性纳米材料与免疫检测试剂",0,{"source":17,"experts":421,"policies":422,"chainCode":154,"aggregationZones":423},[],[],[424,426,428,430],{"city":76,"name":77,"note":425,"level":78},"生命科学仪器与试剂研发",{"city":80,"name":81,"note":427,"level":78},"基因测序与生命科学仪器产业",{"city":83,"name":84,"note":429,"level":9},"（杭州市 · 国家级）：质谱与实验室分析仪器（聚光科技）",{"city":86,"name":87,"note":431,"level":9},"（深圳市 · 国家级）：诊断设备与生命科学仪器产业","2026-10-12T14:28:53.316Z",[],{"id":435,"chainId":4,"layer":436,"segment":437,"name":437,"keyPoints":438,"companies":439,"sortOrder":392,"isKey":455,"checkState":391,"meta":456,"createdAt":469,"links":470},"cnH_E20_02","支撑","CXO医药外包","CRO\u002FCDMO\u002FCMO 临床前\u002F临床",[440,442,445,447,450,452],{"name":36,"note":441},"全流程CRDMO",{"name":443,"note":444},"杭州泰格医药科技股份有限公司","临床CRO",{"name":446,"note":316},"康龙化成",{"name":448,"note":449},"凯莱英医药集团","天津",{"name":451,"note":9},"重庆博腾制药科技股份有限公司",{"name":453,"note":454},"北京昭衍新药研究中心股份有限公司","安评",false,{"source":17,"experts":457,"policies":459,"chainCode":154,"aggregationZones":460},[458],{"org":36,"raw":37,"name":38,"note":39,"title":29},[],[461,463,465,467],{"city":89,"name":90,"note":462,"level":9},"国际生命科学园（无锡市 · 省级）：全流程CRDMO（药明康德）",{"city":83,"name":84,"note":464,"level":9},"（杭州市 · 国家级）：临床CRO与创新药（泰格医药）",{"city":76,"name":92,"note":466,"level":78},"新药研发外包与安评（康龙化成）",{"city":94,"name":95,"note":468,"level":78},"小分子CDMO（凯莱英）","2026-10-12T14:28:53.320Z",[],{"id":472,"chainId":4,"layer":473,"segment":474,"name":474,"keyPoints":475,"companies":476,"sortOrder":494,"isKey":455,"checkState":391,"meta":495,"createdAt":507,"links":508},"cnH_E20_03","中游","小分子创新药","靶向药 PROTAC 分子胶 多肽",[477,479,481,483,486,488,491],{"name":478,"note":9},"江苏恒瑞医药股份有限公司",{"name":480,"note":316},"百济神州",{"name":482,"note":9},"贝达药业股份有限公司",{"name":484,"note":485},"再鼎医药","上海",{"name":487,"note":485},"和黄医药",{"name":489,"note":490},"西安杨森制药有限公司","强生在华重要生产基地，西安草堂基地，1985年成立",{"name":492,"note":493},"西安新通药物研究股份有限公司","1类新药甲磺酸普雷福韦片获批，陕西创新药突破",2,{"source":17,"experts":496,"policies":498,"chainCode":154,"aggregationZones":500},[497],{"org":20,"raw":21,"name":22,"note":23,"title":24},[499],{"raw":335,"date":336,"name":337,"doc_no":9,"issuer":332,"summary":338},[501,503,505],{"city":97,"name":98,"note":502,"level":78},"创新药与生命健康产业",{"city":100,"name":101,"note":504,"level":78},"小分子靶向药（贝达药业）",{"city":103,"name":104,"note":506,"level":78},"创新药与抗肿瘤药（恒瑞医药）","2026-10-12T14:28:53.323Z",[],{"id":510,"chainId":4,"layer":473,"segment":511,"name":511,"keyPoints":512,"companies":513,"sortOrder":528,"isKey":320,"checkState":391,"meta":529,"createdAt":543,"links":544},"cnH_E20_04","生物药与CGT","单抗\u002F双抗\u002FADC CAR-T 基因治疗 mRNA",[514,515,518,519,521,522,525],{"name":480,"note":316},{"name":516,"note":517},"信达生物制药","苏州",{"name":177,"note":168},{"name":230,"note":520},"CAR-T",{"name":233,"note":520},{"name":523,"note":524},"西安巨子生物基因技术股份有限公司","重组胶原蛋白生物材料，港交所上市",{"name":526,"note":527},"陕西佰傲再生医学有限公司","再生医学与组织工程材料",3,{"source":17,"experts":530,"policies":533,"chainCode":154,"aggregationZones":534},[531,532],{"org":168,"raw":169,"name":170,"note":171,"title":172},{"org":162,"raw":163,"name":164,"note":165,"title":166},[],[535,537,539,541],{"city":106,"name":107,"note":536,"level":78},"以西安高新区、西安经开区、西咸新区和杨凌示范区为主要承载",{"city":80,"name":81,"note":538,"level":78},"抗体药与细胞治疗（信达生物）",{"city":109,"name":110,"note":540,"level":111},"生物药与CGT产业化",{"city":113,"name":114,"note":542,"level":78},"生物药与ADC（荣昌生物）","2026-10-12T14:28:53.327Z",[],{"id":546,"chainId":4,"layer":473,"segment":547,"name":547,"keyPoints":548,"companies":549,"sortOrder":560,"isKey":455,"checkState":391,"meta":561,"createdAt":576,"links":577},"cnH_E20_05","疫苗","灭活\u002F重组\u002FmRNA\u002F病毒载体疫苗",[550,553,555,557,559],{"name":551,"note":552},"中国生物技术股份有限公司","国药中生",{"name":41,"note":554},"二价HPV疫苗",{"name":556,"note":554},"万泰生物药业股份有限公司",{"name":558,"note":9},"重庆智飞生物制品股份有限公司",{"name":47,"note":9},4,{"source":17,"experts":562,"policies":565,"chainCode":154,"aggregationZones":567},[563,564],{"org":41,"raw":42,"name":43,"note":44,"title":45},{"org":47,"raw":48,"name":49,"note":50,"title":51},[566],{"raw":352,"date":353,"name":354,"doc_no":9,"issuer":355,"summary":356},[568,570,572,574],{"city":76,"name":116,"note":569,"level":78},"疫苗与生物制品（中国生物）",{"city":118,"name":119,"note":571,"level":78},"疫苗与生物制品（中国医药城）",{"city":121,"name":122,"note":573,"level":78},"疫苗研发生产（沃森生物）",{"city":124,"name":125,"note":575,"level":126},"疫苗与诊断试剂（万泰沧海）","2026-10-12T14:28:53.330Z",[],{"id":579,"chainId":4,"layer":580,"segment":581,"name":581,"keyPoints":582,"companies":583,"sortOrder":597,"isKey":455,"checkState":391,"meta":598,"createdAt":609,"links":610},"cnH_E20_06","下游","注册与商业化","NMPA注册 医保谈判 学术推广",[584,587,590,592,594],{"name":585,"note":586},"上海医药集团股份有限公司","医药商业与创新药推广",{"name":588,"note":589},"国药控股股份有限公司","药品分销",{"name":591,"note":9},"华润医药商业集团有限公司",{"name":593,"note":9},"九州通医药集团股份有限公司",{"name":595,"note":596},"青岛百洋医药股份有限公司","创新药商业化CSO",5,{"source":17,"experts":599,"policies":600,"chainCode":154,"aggregationZones":602},[],[601],{"raw":364,"date":365,"name":366,"doc_no":9,"issuer":367,"summary":368},[603,605,607],{"city":128,"name":129,"note":604,"level":78},"医药流通与供应链（九州通）",{"city":131,"name":132,"note":606,"level":78},"生物医药研发与总部经济",{"city":134,"name":135,"note":608,"level":78},"创新药商业化CSO（百洋医药）","2026-10-12T14:28:53.334Z",[],{"id":612,"chainId":4,"layer":398,"segment":613,"name":613,"keyPoints":614,"companies":615,"sortOrder":13,"isKey":455,"checkState":391,"meta":627,"createdAt":637,"links":638},"cnH_E20_07","CXO研发生产服务","CRO(药物发现\u002F临床前\u002F临床)、CDMO(原料药\u002F制剂\u002F生物药生产外包)",[616,619,620,621,622,624],{"name":617,"note":618},"药明生物技术有限公司","生物药CDMO",{"name":184,"note":185},{"name":187,"note":185},{"name":448,"note":449},{"name":204,"note":623},"生物制药装备",{"name":625,"note":626},"西安泰科迈医药科技股份有限公司","新药研发CRO／CDMO，2011年成立",{"source":17,"experts":628,"policies":629,"chainCode":154,"aggregationZones":630},[],[],[631,633,635],{"city":137,"name":138,"note":632,"level":78},"生物药与ADC CDMO（药明生物）",{"city":97,"name":140,"note":634,"level":78},"质粒与病毒载体CDMO（金斯瑞）",{"city":80,"name":81,"note":636,"level":78},"生物药CDMO与细胞治疗生产","2026-10-12T14:28:53.338Z",[],{"id":640,"chainId":4,"layer":398,"segment":641,"name":641,"keyPoints":642,"companies":643,"sortOrder":16,"isKey":455,"checkState":391,"meta":654,"createdAt":664,"links":665},"cnH_E20_08","生物试剂\u002F培养基\u002F科研","重组蛋白\u002F抗体试剂、细胞培养基、原料药\u002F药用辅料、实验仪器",[644,646,648,649,650,651],{"name":267,"note":645},"分子类生物试剂",{"name":261,"note":647},"重组蛋白与抗体试剂",{"name":264,"note":265},{"name":210,"note":270},{"name":272,"note":273},{"name":652,"note":653},"菲鹏生物股份有限公司","诊断原料",{"source":17,"experts":655,"policies":656,"chainCode":154,"aggregationZones":657},[],[],[658,660,662],{"city":97,"name":142,"note":659,"level":78},"分子类生物试剂（诺唯赞）",{"city":76,"name":92,"note":661,"level":78},"重组蛋白与抗体试剂（义翘神州）",{"city":144,"name":145,"note":663,"level":78},"诊断原料与IVD上游（菲鹏生物）","2026-10-12T14:28:53.342Z",[],{"id":667,"chainId":4,"layer":580,"segment":668,"name":668,"keyPoints":669,"companies":670,"sortOrder":699,"isKey":455,"checkState":391,"meta":700,"createdAt":712,"links":713},"cnH_E20_09","医疗器械\u002F医疗服务\u002F流通","医学影像、IVD体外诊断、生命支持设备、医疗服务终端",[671,673,675,676,679,681,684,687,690,693,696],{"name":288,"note":672},"监护、影像、IVD",{"name":282,"note":674},"高端医学影像",{"name":285,"note":286},{"name":677,"note":678},"爱尔眼科医院集团股份有限公司","医疗服务",{"name":588,"note":680},"器械流通",{"name":682,"note":683},"西安康拓医疗技术股份有限公司","688314，PEEK颅骨修补固定系统国内领先",{"name":685,"note":686},"西安大医集团股份有限公司","放疗设备与医用加速器",{"name":688,"note":689},"西安眼得乐医疗科技有限公司","人工晶状体等眼科植入器械",{"name":691,"note":692},"西安国际医学投资股份有限公司","000516，大型医疗服务集团",{"name":694,"note":695},"陕西医药控股集团派昂医药有限责任公司","医药流通配送",{"name":697,"note":698},"西安怡康医药连锁有限责任公司","医药零售连锁",8,{"source":17,"experts":701,"policies":702,"chainCode":154,"aggregationZones":703},[],[],[704,706,708,710],{"city":147,"name":148,"note":705,"level":78},"高端药品和医疗器械产业聚集区，西安杨森等企业所在地",{"city":144,"name":145,"note":707,"level":78},"医疗器械龙头（迈瑞医疗）",{"city":150,"name":151,"note":709,"level":9},"（上海市 · 市级）：高端医疗装备（联影医疗）",{"city":80,"name":153,"note":711,"level":78},"医疗器械与体外诊断产业","2026-10-12T14:28:53.345Z",[],{"chainId":4,"chainName":5,"matchedTagNames":715,"experts":716,"achievements":718,"topUniversities":720,"note":721},[],{"count":419,"items":717},[],{"count":419,"items":719},[],[],"无标签映射",{"hasMapping":455,"chainId":4,"segments":723},[],[725,727,729,731,733,735,737,739,741,743],{"name":22,"id":726},"cmv7rhowe0022hiky5r26cvh6",{"name":27,"id":728},"cmv7rhowl0027hikya1j3ssn6",{"name":32,"id":730},"cmv7rhowp002chikycghuc75s",{"name":38,"id":732},"cmv7rhowv002hhikyb9z1ebwh",{"name":43,"id":734},"cmv7rhox1002mhikyp2hvg7c7",{"name":49,"id":736},"d409bb67-c458-4c25-a671-54628548bcc5",{"name":55,"id":738},"cmv7rhox7002rhiky4mdiv0lb",{"name":60,"id":740},"cmv7rhoxd002whikyb1h4oiek",{"name":65,"id":742},"2b8699f4-5412-4f7a-b099-61fe099d89d9",{"name":71,"id":744},"cmv7rhoxj0031hikyfjijxnts",{"list":746,"total":786,"page":392,"pageSize":699,"totalPages":560},[747,752,759,764,770,777],{"id":748,"name":749,"category":6,"groupCategory":7,"intro":750,"scale":9,"maturity":10,"checkState":391,"nodeCount":699,"companyCount":751},"ch60_E11","LED与第三代半导体产业链","碳化硅、氮化镓、LED照明、功率器件",92,{"id":753,"name":754,"category":6,"groupCategory":7,"intro":755,"scale":756,"maturity":10,"checkState":391,"nodeCount":757,"companyCount":758},"e0c81c4e-878c-4944-9633-2c202497ef16","云计算与大数据产业链","云服务、数据中心、数据处理、数据交易","中国云计算市场规模约8288亿元（信通院，2024年，同比+34.4%），其中公有云6216亿元；智能算力规模超1590 EFLOPS（工信部，2026-01）",12,163,{"id":760,"name":761,"category":6,"groupCategory":7,"intro":762,"scale":763,"maturity":10,"checkState":391,"nodeCount":699,"companyCount":751},"00ee3af3-fe37-4d60-81ef-2833c238866c","人工智能产业链","AI芯片、大模型、算法框架、AI应用","中国人工智能核心产业规模超1.2万亿元(工信部，2025)",{"id":765,"name":766,"category":6,"groupCategory":7,"intro":767,"scale":9,"maturity":768,"checkState":391,"nodeCount":16,"companyCount":769},"ch60_S02","人才与教育供给链","高等教育、职业教育、人才引进、技能培训","成熟期",28,{"id":771,"name":772,"category":6,"groupCategory":7,"intro":773,"scale":774,"maturity":775,"checkState":391,"nodeCount":699,"companyCount":776},"d5c035fb-13ce-442e-b94e-6ac79b0b5b85","区块链与Web3产业链","区块链底层、联盟链、数字资产、分布式应用","中国区块链市场规模IDC口径2025年超32亿美元；国内区块链信息服务备案编号累计发放20批次4223个（国家网信办《国家信息化发展报告2025》）","孕育期",44,{"id":778,"name":779,"category":6,"groupCategory":780,"intro":781,"scale":782,"maturity":783,"checkState":391,"nodeCount":784,"companyCount":785},"90644f83-8a70-4b3a-ad53-8a2b0e397d5a","卫星互联网","FUTURE","卫星互联网指以低轨星座为基础，提供宽带通信、导航增强、物联网接入等天地一体化信息服务的产业。本链聚焦卫星组网运营、地面设备与终端及行业应用；火箭与卫星制造发射的运载环节归入'商业航天'链。核心工程包括GW星座(中国星网约1.3万颗)与千帆\u002FG60星座(垣信约1.5万颗)。到2030年产业链规模有望突破1.2万亿元(券商口径)。","中国低轨卫星互联网到2030年带动产业链规模有望突破1.2万亿元(券商\u002F机构口径，2026)；2024年起两大星座进入高密度组网","TRL6-8(组网\u002F试运行)；消费终端TRL5-7",15,40,30]